Background: Cardiac troponins are considered the cornestore for risk stratification and diagnosis of patients whit acute coronary syndrome (ACS). Following Clinical Laboratory Standards Institute (CLSI) guidelines, we assessed the analytical performances of the Pathfast ᮋ (Mitsubishi, Japan) cTnI method. Methods: We evaluated different sample types. Control materials and lithium heparin plasma pools were used to determine: limit of blank (LoB), limit of detection (LoD), imprecision and linearity. The effects of potential endogenous interfering substances and the possibility of falsely increased cardiac troponin I (cTnI) concentrations attributable to the presence of heterophilic antibodies (HA), rheumatoid factor (RF) and human anti-mouse antibodies (HAMA) in high concentrations were evaluated. The 99th percentile limit of the cTnI value distribution was determined from 320 Caucasian reference individuals. Results: No significant differences were found when cTnI concentrations of 40 lithium-heparin plasma samples were compared with the matched values of K 2 -EDTA plasma, whole blood and serum samples. The LoB and the LoD of the cTnI method were 0.0048
Introduction
Coronary heart disease is the leading cause of mortality in developed countries (1) . Timely evaluation of patients with chest pain in the emergency/cardiology department is mandatory in order to provide early treatment to reduce morbidity and mortality in those with acute coronary syndrome (ACS). In patients with no ST elevation recorded by ECG, the diagnosis of acute myocardial infarction (AMI) depends almost entirely on serial measurements of biochemical markers of necrosis. In 2000, the European Society of Cardiology (ESC) and the American College of Cardiologists (ACC) recognized the pivotal role of biomarkers, making their increase in the bloodstream the ''cornerstone'' for diagnosis of AMI (2) . In particular, cardiac troponins have emerged as a powerful tool for diagnosis of AMI and for risk assessment of cardiac events, including death and recurrent ischemia (3) . In 2007, the joint ESC/ACCF/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the redefinition of myocardial infarction (4) confirmed the role of troponin. Thus, in a laboratory medicine context, a high-quality analytical method is mandatory (5, 6) . In accordance with Clinical Laboratory Standards Institute (CLSI) guidelines, we evaluated the analytical performance of cardiac troponin I (cTnI) on the Pathfast immunoassay analyzer (Mitsubishi Kagaku Iatron Inc., Tokyo, Japan). We also defined the 99th percentile limit of the cTnI value distribution in our reference population.
Materials and methods

Assay method
The Pathfast system is a bench-top enzyme immunoassay analyzer, processing up to six samples at a time and providing simultaneous quantitative determination of creatine kinase-MB mass, myoglobin, cTnI, and NT-proBNP using whole blood or plasma (sodium or lithium-heparin) samples (7) .
The chemiluminescence enzyme immunoassay (CLEIA) principle has been enhanced by employing an efficient bound/free separation method whereby magnetic particles are washed and separated at the inner wall of a pipette tip according to a patented Magtration ᮋ technology (Precision System Science/PSS USA Inc., Livermore, CA, USA). The term ''Magtration'' is derived by abbreviating ''Magnetic Filtration'': in order to remove excessive reagents or residual materials, the technology performs bound/free separation in pipette tips using magnetic particles. Briefly, the sample (25 mL) containing the target analyte is incubated with magnetic particles coated with the corresponding capture antibodies and alkaline phosphatase (ALP) conjugated antibodies. The resulting immunocomplexes are separated, washed and transferred by Magtration technology to a luminescence measurement well containing a CDP-Star ᮋ reagent (1,2-dioxetane compound Phototope ᮋ ALP) chemiluminescent substrate. The generated luminescence is measured and the analyte concentration calculated using a standard curve relating these two parameters. The cTnI method is a one-step, two site immunoassay using a mouse monoclonal antibody (MoAb A) immobilized on magnetic particles (capture: G00811) recognizing cTnI (residues 41-49), and two monoclonal antibodies (MoAb B and C) bound to ALP (tag: G00821 and G00831) recognizing the cTnI mid (residues 71-116) and C-terminal portion (residues 163-210), respectively. The human cardiac troponin complex (CTI), supplied by Hytest Ltd. (Turku, Finland), was used as calibration material in the Pathfast assay. Upon receiving a new lot of reagents, the specifications of the lot are recorded in the instrument through the master lot entry sheet, included in each package; the calibration adjustment is made using two calibrators supplied with the kit. The working range of the master curve is 0.02-50 mg/L and calibration stability lasts 28 days. All reagents needed for the assay are incorporated into a single cartridge. Analysis time is 15 min.
Sample types
Lithium-heparin plasma samples (polyethylene terephthalate/PET tubes, 68 IU lithium-heparin in 4 mL blood; code: 367374, Becton Dickinson, Franklin Lakes, NJ, USA) were used as reference for the Pathfast cTnI analytical evaluation throughout the entire study. In order to evaluate the potential impact of anticoagulants on cTnI concentrations, EDTA plasma, whole blood (K 2 -EDTA: 1 mg/mL blood, in plastic tubes; code: 368861, Becton Dickinson) and serum (PET tubes without a gel barrier; code: 368815; Becton Dickinson) samples were used. Forty paired samples with detectable cTnI concentrations were obtained from AMI patients admitted to the Cardiology Department of the University Hospital of Bari. cTnI was measured in all sample types within 1 h following collection. cTnI results in whole blood were obtained after software correction for individual hematocrit values, according to the following formula: corrected cTnIsmeasured cTnI/w(1-(Hct/100)x.
Estimation of limit of blank (LoB) and limit of detection (LoD), imprecision studies, linearity on dilution
The LoB and the LoD were calculated according to CLSI EP 17-A (8). The LoB, which is defined as the highest measurement result that is likely to be observed (with a stated probabilitys5%) for a blank sample, was estimated from 60 repeated measurements of the cTnI Pathfast zero calibrator; the analytical signal was expressed in arbitrary units. A sample with a cTnI concentration of 25.3 mg/L was diluted until an expected concentration equal to zero was obtained. The parameters of the linear regression (arbitrary units on the y-axis and expected cTnI concentrations on the x-axis) were used to transform the mean analytical signal of LoB into cTnI concentrations. To determine the LoD, which is defined as the lowest amount of analyte in a sample that can be detected with a stated probability (usually, 95%), a pooled estimate of standard deviations (SDs) was obtained from 12 repeated measurements of five pools with low cTnI concentrations (cTnI concentrations from LoB to ;3=LoB). The imprecision of the cTnI Pathfast method was determined in accordance with CLSI EP5-A guidelines (9): a lithium-heparin plasma pool and BioRad Liquicheck ீ Cardiac Markers control LT (level 2, 3) (BioRad Laboratories, Headquarters, Hercules, CA, USA) were analyzed daily, in duplicate, for 20 consecutive days. Two aliquots of test material, for each concentration, were tested within each run (80 measurement per sample). To define the method imprecision in the low concentration range, a plasma pool containing a known troponin concentration (0.11 mg/L) was serially diluted with a lithium-heparin plasma sample showing undetectable concentrations of cTnI. Eleven pools containing troponin concentrations ranging from 0.1 to 0.01 mg/L were aliquoted and stored frozen at -208C until analysis. For each of the 11 pools, a new aliquot was thawed, centrifuged and analysed in duplicate every day for 10 consecutive days; two different reagent lots and two different calibration curves were used. The linearity of the method was determined according to CLSI guidelines EP6-P (10) 
Effect of potential interfering substances
Lithium-heparin plasma pools (P) containing high concentrations of potentially interfering substance (total bilirubin,
and TnI concentrations lower than the detection limit were prepared. These were added in fixed ratios (0q10, 1q9, 2q8, 3q7, 4q6, 5q5, 6q4, 7q3, 8q2, 9q1, 10q0) to two lithium-heparin plasma pools containing elevated TnI concentrations (S1: 1.13 mg/L; S2: 2.72 mg/L) and physiological concentrations of each of the potential interfering substances. In addition, diluting both the S1 and S2 pools (in the same fixed ratios mentioned above) with a lithium-heparin plasma pool with undetectable concentrations of TnI allowed us to produce a set of control dilutions (control-1, C1; control-2, C2).
To evaluate the potential interference due to heterophilic antibodies (HA), human anti-mouse antibodies (HAMA) and rheumatoid factor (RF), 12 lithium heparin plasma samples known to cause false positive cTnI results when tested with the Dimension RxL (Siemens Healthcare Diagnostics, Deerfield, IL, USA), and seven commercially available (Scantibodies Inc, Santee, CA, USA) samples containing high HAMA (concentration range: 100-782 ng/mL) and RF titers (concentration range: 162-1080 UI/mL) were tested using the Pathfast method. All these samples were treated with heterophile blocking tubes (Scantibodies Inc).
Comparison study
The Pathfast cTnI method was compared to the Stratus CS cTnI method (Siemens Healthcare Diagnostics) in accordance with CLSI guidelines (11) . A total of 115 paired lithiumheparin plasma samples were collected and cTnI concentrations measured with the Stratus CS and Pathfast. In the comparison study, only samples with cTnI concentrations )0.015 mg/L (LoD for Stratus CS) and lower than 50 mg/L (linearity limit for Pathfast) were used.
Upper reference limit
In order to define the cTnI upper reference limit, lithium-heparin plasma samples were collected from 320 healthy Caucasian subjects: (160 women and 160 men aged 26-89 years; mean"SDs56.7"15.6 years). Exclusion criteria included subjects with a suspected history of ACS, biochemical abnormalities in serum creatinine, glucose, urea, alanine aminotransferase (ALT), aspartata aminotransferase (AST), C-reactive protein, creatine kinase-MB, leukocyte blood count, or hemoglobin and hyperpyrexia. According to the ESC/ACCF/AHA/WHF (2, 4), the upper reference limit was calculated at the 99th percentile limit of the cTnI value distribution in the reference group; the 95% confidence interval (CI) for the percentile was determined assuming a nonGaussian distribution of the data.
Statistical analysis
Statistical comparison among different sample types was assessed with the Wilcoxon rank sum test for paired samples; Deming regression and Bland-Altman analysis (12) were also performed.
For 60 measured values of the sample blank, a Gaussian distribution was not assumed (Anderson-Darling-test: p-0.01) and the 95th percentile of the LoB was calculated as w60(95/100)q0.5x ordered observations following logarithmic transformation of the original data set. The LoD was defined by the relation LoDsLoBqc b =SDs. SDs is the pooled estimate of the SD of pools with low cTnI concentrations, and c b sz 1-b /(1-1/(4=f)) where the z 1-b is the standard normal deviation (SDs1.645), and f is the number of degrees of freedom for estimation of SDs (13) . ANOVA was used to assess the total imprecision (CV%) for the cTnI method at different concentrations of analyte. Dilution linearity was determined by least-squares linear regression analysis with the lack-of-fit-test (10). Bland-Altman analysis was used to evaluate the effect of potentially interfering endogenous substances. We considered the significance of the bias on the basis of the 95% CI. Taking into account the analytical imprecision of the method, a difference )10% among results obtained in pools with and without added substances was considered to be clinically significant. Correlation between Pathfast and Stratus CS cTnI methods were assessed using Passing and Bablok regression (14) and Bland-Altman analysis.
Statistical analysis was performed using Analyse-it Software for Microsoft Excel version 2.11 (Analyse-it Software, Leeds, UK) and MedCalc version 9.5 (Mariakerke, Belgium). Figure 1A shows the imprecision profile at low cTnI concentrations. A cTnI concentration of 0.02 mg/L was associated with a total imprecision -10% (CVs9.6%). Linearity data showed that the linearity hypothesis was accepted (Fs2.33; ps0.11), and a linear response obtained (r higher than the 99th percentile upper reference limit obtained in this study, suggesting interference by HA, as also shown by pre-treatment. cTnI concentrations after treatment with heterophilic blocking tubes were lower than detection limit of the assay. The other samples that showed spuriously high concentrations of troponin when measured with the RxL Dimension, including those with high RF and HAMA concentrations, gave troponin I results below the detection limit of the method when tested on Pathfast.
Results and discussion
Comparison (ns115) between Pathfast (y) and Stratus CS (x) cTnI gave the following correlation: ys0.336(SE, 0.009)x-0.005 (SE, 0.12) mg/L; rs0.98 (ns115). Figure 1B shows the bias plots. The mean absolute bias was y2.7 mg/L (95% CI, -3.8 to -1.4) and mean percentage bias was -112% (95% CI, -118.9 to -104.9). The intercept was not significant and methods showed a constant bias. The 99th (95% CI) percentile limit of the cTnI values distribution in the reference population was 0.013 (0.0068-0.019) mg/L: measurable cTnI concentrations (i.e., )0.0066 mg/L, assay LoD) were found in only six subjects (2%). Figure 1A shows the imprecision (28.7% CV) obtained with a sample with a cTnI value of 0.013 mg/L. Several assays with relatively high precision for cTnI measurement exist. However, none are able to experimentally achieve a 10% CV at the 99th percentile limit of the reference population (15) ; this is true also for the cTnI Pathfast method.
In conclusion, this study indicates that the cTnI Pathfast method meets the quality specifications recommended by NACB and the IFCC Committee for the Standardization of Cardiac Damage (5, 6) . Therefore, it may be suitable for use in the clinical laboratory to help clinicians in the management of ACS patients. Caution should be taken when comparing the published findings related to analytical sensitivity of the cardiac troponin assays, with the findings of this study. Many LoD values are experimentally calculated as LoB (e.g., as the concentration corresponding to a signal of 3 SD above the mean of N replicates for a sample in which cTnI is absent), so that they can be markedly lower if more statistically rigorous procedures, like those applied in this study, were used.
